Improving Care for ‘Patients of All Ages’ Is GBT’s Goal, Exec Says

Improving Care for ‘Patients of All Ages’ Is GBT’s Goal, Exec Says

297657

Improving Care for ‘Patients of All Ages’ Is GBT’s Goal, Exec Says

Global Blood Therapeutics (GBT) is currently focused on expanding the use of Oxbryta (voxelotor) to children, ages 4–11, with sickle cell disease (SCD). But research into its use with younger children, as well as studies into other potential SCD therapies, are also underway. “Sickle cell disease patients of all ages worldwide need improved care now; we are stepping up to the challenge,” Kim Smith-Whitley, MD, GBT’s executive vice-president and head of research and development, said in an emailed statement…

You must be logged in to read/download the full post.